E. Prat-Colilles, J.J. Lluch-Galcerá, M. Martinez-Molina, J.M. Carrascosa Carrillo
{"title":"Sporotrichoid Lymphocutaneous Presentation in Ulcerative Cutaneous Alternariosis: A Phaeohyphomycosis Case in a Renal Transplant","authors":"E. Prat-Colilles, J.J. Lluch-Galcerá, M. Martinez-Molina, J.M. Carrascosa Carrillo","doi":"10.1016/j.ad.2023.12.010","DOIUrl":"10.1016/j.ad.2023.12.010","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages 905-907"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Prat-Colilles, J.J. Lluch-Galcerá, M. Martinez-Molina, J.M. Carrascosa Carrillo
{"title":"[Artículo traducido] Alternariosis cutánea con patrón linfocutáneo esporotricoide: un caso de feohifomicosis en paciente trasplantado renal","authors":"E. Prat-Colilles, J.J. Lluch-Galcerá, M. Martinez-Molina, J.M. Carrascosa Carrillo","doi":"10.1016/j.ad.2025.05.023","DOIUrl":"10.1016/j.ad.2025.05.023","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages T905-T907"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Muntaner-Virgili, C. Torrecilla-Vall-llossera, M. Bonfill-Ortí, I. Figueras-Nart
{"title":"[Artículo traducido] Efectividad y seguridad en el uso de inhibidores de Janus kinasa en combinación con otros tratamientos sistémicos clásicos o biológicos: experiencia en práctica clínica real","authors":"C. Muntaner-Virgili, C. Torrecilla-Vall-llossera, M. Bonfill-Ortí, I. Figueras-Nart","doi":"10.1016/j.ad.2025.06.001","DOIUrl":"10.1016/j.ad.2025.06.001","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages T927-T931"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Oteiza Rius , J. Antoñanzas , P. Redondo , A. Morelló Vicente , R. Salido Vallejo
{"title":"[Translated article] Application of Transmurally Suspensory Suture in the Medial Rotation Flap for Surgical Defects of the Nasal Ala","authors":"I. Oteiza Rius , J. Antoñanzas , P. Redondo , A. Morelló Vicente , R. Salido Vallejo","doi":"10.1016/j.ad.2025.06.010","DOIUrl":"10.1016/j.ad.2025.06.010","url":null,"abstract":"<div><div>Reconstructing the nasal pyramid presents a significant challenge due to its anatomical complexity and need to preserve the functionality of the internal nasal valve and maintain facial symmetry. This study provides a retrospective analysis of 12 cases in which an alar rotation flap was employed to reconstruct surgical defects in the nasal ala. It outlines the fundamental keys of the procedure and provides practical considerations aimed at preventing nose pincushioning and alar asymmetry. Functional and esthetic outcomes were assessed, revealing the absence of complications and high satisfaction scores at the follow-up, which adds to the objective evaluation of the results. These findings confirm the feasibility of the alar rotation flap as an effective and versatile option, especially to address small defects in the nasal ala. Additionally, we propose 2 strategies to improve functional and esthetic outcomes alike.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages T892-T896"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Fernández-de-Misa , M. Montes-de-Oca , I. Loizate , N. Hernández-Hernández
{"title":"Carcinomas basocelulares múltiples. Patocronia y factores predisponentes","authors":"R. Fernández-de-Misa , M. Montes-de-Oca , I. Loizate , N. Hernández-Hernández","doi":"10.1016/j.ad.2024.10.070","DOIUrl":"10.1016/j.ad.2024.10.070","url":null,"abstract":"<div><h3>Introduction</h3><div>Between 29% and 53% of the patients who develop basal cell carcinoma (BCC) will develop new BCCs.</div></div><div><h3>Objectives</h3><div>Current objectives are to analyze the proportion and basic characteristics of patients who develop BCC<!--> <!-->> 1, to delineate the concept of multiple BCC (mBCC) and be able to identify the factors associated with its development, and analyze its timeframe.</div></div><div><h3>Patients and method</h3><div>We conducted a retrospective observational study including all patients diagnosed with sporadic BCC from January 1<sup>st</sup>, 2014 through December 31<sup>st</sup>, 2014 at a tertiary referral center. Data included dates of BCCs, gender, age and histology of the first BCC, and the presence of BCC<!--> <!-->> 1 at the initial appointment (<em>cluster</em><sup><em>+</em></sup>). mBCC was defined as a patient who developed a series of BCCs<!--> <!-->> the 75<sup>th</sup> percentile of the series.</div></div><div><h3>Results</h3><div>A total of 758 patients (51.2% men), were included. After a median follow-up of 100 months, 52.8% of the patients developed BCC<!--> <!-->> 1. The 75<sup>th</sup> percentile of the number of BCCs was 3. Factors associated to mBCCs included being <em>cluster</em><sup><em>+</em></sup> (OR, 5.6; 95%<span>C</span>I, 3.2 – 9.7), being men (OR, 3.1; 95%CI, 2.0 – 4.8) and diagnosed with the first BCC between ages of 50 and 80 years (OR, 2.1; 95%CI, 1.3 – 3.5). After 5 years, 54% of patients exhibiting these 3 factors developed mBCC. The estimated median time to mBCC was 38.00 months (95%CI, 0 – 79.71).</div></div><div><h3>Conclusions</h3><div>A quarter of patients who Exhibit 1 BCC eventually develop 4 or more BCCs. Analyzing routine parameters may help identify individuals at a higher risk of developing mBCC and predict its timeframe.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages 815-823"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Butrón-Bris , M. Llamas-Velasco , S. Armesto , A. Sahuquillo-Torralba , J. Pujol-Montcusí , R. Ruiz-Villaverde , A. Martínez-López , P. de la Cueva , A. Romero-Maté , G. Roustan , E. Vilarrasa-Rull , M. Ferrán-Farrés , M.C. Ovejero-Benito , C. Palomar-Moreno , M. Navares , J. Novalbos , F. Abad-Santos , E. Daudén , H. de la Fuente
{"title":"Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice","authors":"B. Butrón-Bris , M. Llamas-Velasco , S. Armesto , A. Sahuquillo-Torralba , J. Pujol-Montcusí , R. Ruiz-Villaverde , A. Martínez-López , P. de la Cueva , A. Romero-Maté , G. Roustan , E. Vilarrasa-Rull , M. Ferrán-Farrés , M.C. Ovejero-Benito , C. Palomar-Moreno , M. Navares , J. Novalbos , F. Abad-Santos , E. Daudén , H. de la Fuente","doi":"10.1016/j.ad.2025.03.030","DOIUrl":"10.1016/j.ad.2025.03.030","url":null,"abstract":"<div><h3>Background</h3><div>Numerous studies have investigated the association that exists between genetic variants and the efficacy profile of biologic therapies for the management of psoriasis. However, as far as we know, data on this association for brodalumab are lacking in the currently available scientific literature.</div></div><div><h3>Objectives</h3><div>To analyze the association of 180 polymorphisms with an optimal response to brodalumab in real-world clinical practice.</div></div><div><h3>Methods</h3><div>A total of 119 patients with plaque psoriasis on a 24-regimen of brodalumab recruited from 11 Spanish hospitals were genotyped for 180 polymorphisms. Optimal response was evaluated as absolute (PASI)<!--> <!-->≤<!--> <!-->1 at 6 and 12 months. Polymorphisms with false discovery rates<!--> <!--><<!--> <!-->0.25 were included in a multiple regression model.</div></div><div><h3>Results</h3><div>A total of 68% and 62% of patients achieved PASI<!--> <!-->≤<!--> <!-->1 at 6 and 12 months, respectively. Patient weight, history of biological therapy, disease-modifying anti-rheumatic drugs, and psoriatic arthritis were identified as risk factors for failing to achieve PASI<!--> <!-->≤<!--> <!-->1. At 12 months, polymorphisms rs495337 (SPATA2), rs6311 (HTR2A), and rs4085613 (LCE3D) were associated with achieving a PASI<!--> <!-->≤<!--> <!-->1 regardless of previous use of biologics and DMARDs, psoriatic arthritis, or weight. The genotypes CT-TT for rs6311 (HTR2A) and GT for rs4085613 (LCE3D) were identified as risk factors for lack of optimal response at 12 months, while genotypes AG-AA for rs495337 (SPATA2) increase the probability of response. No polymorphism was associated to brodalumab response at 6 months.</div></div><div><h3>Conclusions</h3><div>This study identified genetic variations associated with the ability to achieve an optimal response to brodalumab, providing potential insights into its efficacy profile for treating plaque psoriasis.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 8","pages":"Pages 824-829"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}